AtriCure Q4 2023 Adj EPS $(0.21) Beats $(0.23) Estimate, Sales $106.50M Beat $103.68M Estimate
Portfolio Pulse from Benzinga Newsdesk
AtriCure (NASDAQ:ATRC) reported Q4 2023 adjusted EPS of $(0.21), surpassing the $(0.23) estimate, with sales of $106.50M exceeding the $103.68M forecast. This represents a 20.98% increase in sales compared to the same period last year.
February 15, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AtriCure reported a Q4 2023 adjusted EPS of $(0.21), beating estimates, and sales of $106.50M, also above expectations. This indicates a strong performance and a significant year-over-year sales growth of 20.98%.
AtriCure's better-than-expected Q4 2023 earnings and sales figures, coupled with a significant year-over-year sales growth, suggest a positive outlook for the company. This performance could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100